Advanced gynecologic radiotherapy only works when target volume delineation and field setup remain dependable despite daily shifts in the bladder, rectum, and uterus. This chapter narrows the discussion to the technologies that matter most in practice: image-guided IMRT, bone marrow sparing, adaptive re-planning, proton therapy, and carefully selected SBRT use in cervical and endometrial disease.
The reason is straightforward. Outcomes for locoregionally advanced gynecologic malignancies remain suboptimal, and treatment-related toxicity still limits how fully therapy can be delivered. In that setting, technology is useful only if it helps dose escalation, toxicity reduction, or both. For the broader series context, see the Target Volume Delineation and Field Setup – Complete Clinical Guide. If you want the external beam foundation before coming back to advanced delivery, review our dedicated articles on definitive gynecologic target delineation and postoperative gynecologic target delineation.
In this article
Principles of advanced gynecologic radiotherapy
The chapter opens with a dual objective: intensify treatment where possible and lower toxicity whenever that can be done safely. IMRT has become an accepted standard modality for definitive and postoperative external beam radiotherapy in cervical and endometrial cancer, although the authors still note some controversy around routine implementation because prospective randomized data remain limited.
Even with that caution, the clinical direction is consistent. Daily IG-IMRT improves localization of both targets and organs at risk, which allows more conformal plans while maintaining tumoricidal dose. Adaptive re-planning addresses an anatomy that changes during treatment. Bone marrow-sparing IMRT aims to reduce hematologic toxicity. SBRT is framed as a boost option for patients who cannot receive brachytherapy, for re-irradiation, localized recurrence, and limited metastatic disease. Proton therapy is included because its distal dose fall-off may reduce toxicity, although high-quality head-to-head evidence against conventional radiotherapy and IMRT remains limited.
Image guidance and daily target verification
The chapter makes the practical point early: pelvic IMRT is only as good as the imaging workflow that supports it. Sophisticated conformal planning can reduce the treated volume, but only if target structures and OARs are delineated accurately and organ motion plus setup uncertainty are managed properly. In the pelvis, those variables change both during treatment and between fractions.
According to the chapter, IG-IMRT has been associated with improvements in hematologic and gastrointestinal toxicity compared with IMRT alone [1, 2]. Daily on-board orthogonal kV images can align bony anatomy to the reference position established at CT simulation. Daily CBCT adds a more useful look at rectal and bladder filling at the time of treatment. When a shape model-based planning target volume expansion strategy is combined with daily CBCT, target coverage inside the 95% isodose cloud is reported as excellent [3].
The figure in the chapter shows exactly why that matters. The patient had FIGO 2009 IIB cervical cancer with pelvic and para-aortic involvement. A change in bladder and rectal filling moved part of the uterine fundus outside the PTV before one of the daily fractions. That is the kind of miss advanced gynecologic radiotherapy is supposed to prevent, and daily image guidance is the operational tool that makes the correction possible.
Bone marrow-sparing IMRT
Bone marrow sparing is presented as a toxicity-reduction strategy for patients receiving pelvic radiotherapy, often together with chemotherapy. The chapter states that this IMRT approach has already been shown to reduce hematologic toxicity [2, 4], then walks through several ways to define the marrow target that deserves protection.
With PET/CT, the method is to contour the pelvic bones and define active marrow as the regions whose SUV exceeds the mean SUV within the bones, then apply marrow constraints [2, 5]. If PET/CT is unavailable, the chapter lists two workable alternatives: an atlas-based approach and CT-based demarcation of the low-density regions within the bones, again followed by dose constraints [4, 5]. The practical takeaway is not that one segmentation method is uniquely correct, but that marrow has to be treated as an explicit planning structure.
Dose constraints listed for bone marrow
The chapter separates total pelvic bone marrow from active bone marrow and gives both soft and hard objectives derived from NTCP modeling. The exact values matter, because these are the numbers the planner has to negotiate against competing target requirements.
| Structure | Constraint level | Mean dose | V10 | V20 |
|---|---|---|---|---|
| Pelvic bone marrow | Soft constraint | ≤ 27 Gy | ≤ 85.5% | ≤ 66% |
| Pelvic bone marrow | Hard constraint | ≤ 29 Gy | ≤ 90% | ≤ 75% |
| Active bone marrow | Soft constraint | ≤ 28.5 Gy | ≤ 90% | ≤ 70% |
| Active bone marrow | Hard constraint | ≤ 30 Gy | ≤ 90% | ≤ 75% |
Source: Target Volume Delineation and Field Setup, 2nd Edition
These limits are useful because they distinguish an ideal objective from a ceiling that should be harder to violate. They also reinforce the chapter’s broader planning logic: sparing marrow is not a separate project from target coverage, but part of the same pelvic dose negotiation.
Adaptive re-planning
Adaptive re-planning is included because the treated anatomy does not stay fixed across the course. The chapter divides adaptive radiotherapy into three categories: offline between fractions, online immediately before a fraction, and real-time during treatment delivery. That framework is clinically useful because each mode addresses a different timescale of anatomical change.
The authors then describe several concrete strategies. One is a plan-of-the-day workflow that builds a patient-specific library of plans covering different target volumes and organ motion patterns, with pre-treatment CBCT selecting the closest match on any given day. Another is scheduled re-planning with weekly MRI. Deformable image registration can model accumulated dose to targets and OARs. More advanced treatment planning systems may also provide automated dose monitoring and dose-volume metrics that can be reviewed offline to decide whether re-planning has become necessary.
Adaptive strategies named in the chapter
These approaches are all listed explicitly in the source text. Putting them side by side helps clarify that adaptive radiotherapy is a toolkit rather than a single intervention.
| Strategy | Timing | How the chapter describes it |
|---|---|---|
| Plan-of-the-day | Before each fraction | A patient-specific plan library is created, and pre-treatment CBCT selects the plan that best matches the day’s target and OAR configuration. |
| Scheduled re-planning | During the course | Can be performed with weekly MRI. |
| Deformable image registration | Offline or with interim imaging | Used to model accumulated dose to targets and OARs and to support new plans from pre-treatment imaging and/or MRI or PET/CT. |
| Automated dose monitoring | Offline | Advanced systems can review dose-volume metrics to guide the decision to re-plan. |
| Online ART | Immediately before treatment | Emerging platforms integrate iterative CBCT for dose calculation and daily re-planning, or MRI-based online re-planning. |
Source: Target Volume Delineation and Field Setup, 2nd Edition
For offline ART, the chapter specifically recommends considering a new plan when the patient develops substantial weight loss or a meaningful change in target size. A repeat simulation may be required if treatment-room imaging is not adequate for re-planning. Online ART is aimed at another problem: the day-to-day change in bladder and rectal filling that can shift both target and OARs in ways the simulation CT never fully captured.
Proton therapy
Proton therapy is presented as a dosimetric sparing tool. Compared with photons, protons combine a relatively gradual dose build-up with a sharp fall-off distal to the target. That physical behavior may reduce dose to organs at risk beyond the incident fields and lower the integral dose while preserving adequate target coverage.
The chapter highlights a few scenarios where that advantage may matter most. Para-aortic nodal treatment and re-irradiation are specifically called out as settings in which protons may outperform IMRT. Dosimetric and early clinical studies suggest lower dose to bowel, bladder, and bone marrow compared with IMRT [9]. In premenopausal women, proton planning may also improve ovarian sparing, for example by keeping one ovary below a mean dose of 15 Gy [10]. For definitive treatment, the target dose should match photon prescriptions, accounting for an assumed proton relative biological effectiveness of 1.1.
Planning details also change with the modality. PTVs become beam-specific because of range uncertainty, and beam arrangements should avoid putting critical structures distal to the target. The representative case in the chapter involved a 39-year-old woman with FIGO 2009 IIB cervical cancer and pelvic nodal involvement who also had active lupus nephritis requiring hemodialysis. She received 39.6 Gy in 22 fractions to the pelvis, a boost of gross nodal disease to 51.6 Gy, and then a brachytherapy boost of 30 Gy in 4 fractions.
The chapter also describes a proton boost scenario for patients who cannot undergo brachytherapy. In that setting, protons may have dosimetric advantages over VMAT in the bladder, bowel, femoral heads, and rectum. One example is to define the boost CTV from MRI obtained after 3 weeks of chemoradiation and deliver 30 Gy/Gy equivalent in 5 fractions instead of brachytherapy [11]. The caution at the end is important: high-quality prospective evidence is still lacking, so better dosimetry should not automatically be treated as proven clinical benefit.
SBRT in cervical and endometrial cancer
SBRT is treated as a selective tool, not as a routine replacement for brachytherapy. It allows high doses to be delivered in 1 to 5 fractions, but only if target visualization, tumor and OAR delineation, and image-guided setup are all highly reliable. In gynecologic disease, that threshold for technical discipline is non-negotiable.
Cervical cancer
For locoregionally advanced cervical cancer, the standard of care remains daily fractionated EBRT with concurrent cisplatin-based chemotherapy followed by a brachytherapy boost, with a final target EQD2 of 80 to 95 Gy. The chapter is explicit on that point. Eligible patients should still receive brachytherapy.
SBRT enters the picture in narrower situations: patients who cannot receive brachytherapy because of severe comorbidities, patients who refuse brachytherapy, especially those at risk for posttraumatic stress disorder, nodal boost cases, re-irradiation, localized recurrence, and limited metastatic disease [12-16]. The text acknowledges that SBRT can produce a conformal high-dose boost, but it also gives a strong warning. A phase II trial that used SBRT at 28 Gy in 4 fractions as a brachytherapy replacement closed early because of concern over higher-than-expected toxicity and lower-than-expected 2-year local control, progression-free survival, and overall survival [17].
For patients who truly will not undergo brachytherapy, the chapter mentions a five-fraction option of 27.5 Gy in 5 fractions after 45 Gy to the pelvis, yielding an EQD2 of 80 Gy with α/β = 10. The illustrated example is a 52-year-old woman with FIGO 2009 IB1 cervical cancer who was neither a surgical candidate nor a brachytherapy candidate because of comorbidities. She received 45 Gy in 25 fractions to the pelvis followed by an SBRT boost of 30 Gy in 5 fractions, and fiducial markers were placed before simulation.
Endometrial cancer
In endometrial cancer, the role of SBRT is also selective. The chapter considers it as an alternative boost modality in postoperative disease, as a way to boost lymph nodes, and as an option for re-irradiation or metastasis-directed treatment. The clearest quantitative data come from a retrospective series of recurrent, persistent, or oligometastatic disease treated with a median of 24 Gy, ranging from 10 to 50 Gy, in a median of 4 fractions, ranging from 1 to 6 fractions. One-year and three-year local control were 80% and 68%, respectively, with better control in smaller tumors. Grade ≥ 2 toxicity was 4.3%, with only one grade 3 event and no grade 4 or 5 toxicities [25].
SBRT dose scenarios cited in the chapter
The numbers below help separate reasonable use from overreach. In gynecologic SBRT, indication matters as much as dose.
| Scenario | Dose and fractionation | What the chapter emphasizes |
|---|---|---|
| Phase II brachytherapy replacement trial | 28 Gy in 4 fractions | The study closed early because toxicity was higher than expected and 2-year outcomes were worse than expected. |
| Option for patients who will not receive brachytherapy | 45 Gy to the pelvis plus 27.5 Gy in 5 fractions | Produces an EQD2 of 80 Gy with α/β = 10. |
| Illustrative cervical case | 45 Gy in 25 fractions plus 30 Gy in 5 fractions | Used in a FIGO 2009 IB1 patient who was not a surgical or brachytherapy candidate. |
| Five-fraction regimens in general | Typically 4-8 Gy per fraction | Fractions of 8-15 Gy have also been reported; target size, prior radiotherapy, and nearby OAR tolerance must guide the choice. |
| Retrospective endometrial series | Median 24 Gy (range 10-50) in median 4 fractions (range 1-6) | Local control was 80% at 1 year and 68% at 3 years; grade ≥ 2 toxicity was 4.3%. |
Source: Target Volume Delineation and Field Setup, 2nd Edition
The chapter ends on a deliberately conservative note. Advanced technologies expand what can be planned and delivered in gynecologic radiotherapy, but they only perform well when indication, anatomy management, and image guidance stay tightly linked. To reconnect these details with the broader field arrangement strategy, return to the complete guide and keep the dedicated definitive and postoperative articles nearby.
